Alaunos Therapeutics, INC 8-K filings

Alaunos Therapeutics will implement a 1-for-15 reverse stock split effective January 31, 2024, to maintain Nasdaq listing compliance.

Alaunos Therapeutics has appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer, effective January 20, 2024, while he continues to serve on the Board.